Autism Spectrum Disorders (ASD) represent a heterogeneous group of neurodevelopmental conditions
characterized by altered maturation and connectivity of brain networks.
From a clinical perspective, ASD is typically characterized by:
Comorbidità frequenti:
The prevalence of ASD has increased over the past decades, partly due to the broadening of diagnostic criteria and greater clinical and social awareness. It is estimated that more than1 in 100 children are affected by an autism spectrum disorder. In Italy, according to data from the Istituto Superiore di Sanità, approximately 1 in 77 children aged 7 to 9 receive an ASD diagnosis, with a markedly higher prevalence in males, who are about 4.4 times more likely to be affected compared to females¹.
1. Istituto Superiore di Sanità. Disturbi dello spettro autistico nei bambini e negli adolescenti. Linea guida 2023.
Scientific evidence indicates that genetic factors play a predominant role in the development of autism, accounting for approximately 70–90% of cases.²⁻³
Genetic abnormalities may include:
2. Tick B et al. Heritability of autism spectrum disorders: a meta-analysis of twin studies. JAMA Psychiatry. 2016;73(3): 258-268.
3. Sandin S et al. The familial risk of autism. JAMA. 2014;311(17):1770-1777.
4. Satterstrom FK et al. Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell. 2020;180(3):568-584.e23.
5. Iossifov I et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515:216-221.
6. Rolland T, et al. Phenotypic effects of genetic variants associated with autism Nat Med. 2023 Jul;29(7):1671-1680.
7. Grove J et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51:431-444.
PRENATALAUTISM is an advanced non-invasive prenatal screening test that analyzes circulating cell-free fetal DNA (cfDNA) from a maternal blood sample to identify fetal mutations responsible for severe genetic diseases associated with Autism Spectrum Disorders. This stateof- the-art approach offers superior accuracy and detection capabilities compared to conventional NIPTs.
PRENATALAUTISM is an advanced non-invasive prenatal screening test that analyzes circulating cell-free fetal DNA (cfDNA) from a maternal blood sample to identify fetal mutations responsible for severe genetic diseases associated with Autism Spectrum Disorders. This stateof- the-art approach offers superior accuracy and detection capabilities compared to conventional NIPTs.
Screening for 300+ genetic diseases associated with Autism Spectrum Disorders (ASD).
Screening for 300+ genetic diseases associated with ASD.
The test also allows the detection of:
Provides the most comprehensive level of screening, enabling the investigation of the fetus for:
PrenatalAutism | N° | Basic | Karyo | Genetics |
---|---|---|---|---|
Genetic diseases associated with ASD | 300+ | |||
De novo genetic conditions | 1000+ | |||
Common inherited genetic disorders | 1000+ | |||
Common and rare chromosomal aneuploidies | 24 cromosomes | |||
Segmental deletions and duplications | > 7Mb | |||
Microdeletion/microduplication syndromes | 130+ | |||
Specific microdeletions/microduplications associated with ASD | 23 |
The advanced high-resolution fetal genome sequencing technology⁸⁻⁹, combined with sophisticated
bioinformatic analysis using a proprietary algorithm, enables the study of the fetal karyotype and the
screening of hundreds of severe genetic disorders in the fetus, including those associated with Autism
Spectrum Disorders, inherited conditions, and de novo diseases, in a single analysis. This level of detail was
previously achievable only through invasive prenatal diagnostic methods
The high resolution of the test allows for a low limit of detection (LOD).
Highly accurate at 1%
of Fetal Fraction
The high resolution of the test allows for a low limit of detection (LOD).
Highly accurate at1% of Fetal Fraction
8. Brand H, Whelan CW, Duyzend M, et al. High-resolution and noninvasive fetal exome screening. N Engl J Med. 2023;389:2014-2016.
9. Miceikaitė I, Hao Q, Brasch-Andersen C, et al. Comprehensive Noninvasive Fetal Screening by Deep Trio-Exome Sequencing. N Engl J Med. 2023;389:2017-2019.
The test result may be negative, indicating a low risk for a chromosomal abnormality or a genetic disease in the fetus. In such cases, the pregnancy may proceed without any need for follow-up.
In some cases, the test result may be positive, indicating a higher risk for a chromosomal abnormality or a genetic disease in the fetus. Such instances require follow-up with invasive prenatal diagnostic techniques (amniocentesis or chorionic villus sampling) to confirm the findings.
Follow-Up for Positive Results
Amniocentesis or chorionic villus sampling to confirm the detected chromosomal anomaly or genetic disease.
Complimentary services
A simple blood sample collected at 10^ weeks of gestation is required
Low limit of detection: highly accurate at low cfDNA quantity (FF:1%)
Groundbreaking technologies and advanced bioinformatic analysis
Sensitivity and specificity <99%
Detection of both genome-wide chromosomal abnormalities and single gene disorders, providing the most comprehensive information available from a non-invasive prenatal test to date
Pre-clinical validation studies performed on a wide cohort of pregnant women
PRENATALAUTISM represents the ideal solution to provide in-depth and personalized information, tailored to the needs of each couple.
GENOMICA is a highly innovative company with extensive technical and scientific expertise, active in both clinical applications and research. Supported by a team with over 20 years of experience in molecular diagnostics, GENOMICA combines cutting-edge technology with a strong commitment to innovation, delivering increasingly accurate and accessible diagnostic services.
GENOMICAis a highly innovative company with extensive technical and scientific expertise, active in both clinical applications and research. Supported by a team with over 20 years of experience in molecular diagnostics, GENOMICA combines cutting-edge technology with a strong commitment to innovation, delivering increasingly accurate and accessible diagnostic services.
Fill out this form for a free consultation.
One of our professionals will contact you, free of charge and without obligation, to provide you with all the information you need